News

Fycompa is indicated to treat PGTC seizures in adult and adolescent patients from 12 years of age with idiopathic generalized epilepsy. Discovered and developed by Eisai, Fycompa is

The drug is indicated for ADPKD patients who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease. Tolvaptan

The company said that Viberzi has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist and a kappa receptor agonist. IBS-D is characterized

Under the deal, the parties plan to pursue development and commercialization of Vibativ in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). The company said that additional indications

These three new patents extend protection to include all formats and formulations of RPE cells, including suspensions and sheets of cells, for use as therapeutic agents, and the

The Generex proprietary RapidMist drug delivery platform technology administers active pharmaceutical ingredient via aerosolized metered dose spray into the mouth for rapid absorption by the buccal mucosa. The

The companies have agreed to begin feasibility studies to evaluate how selected Novartis’ proprietary biologics can be delivered into the bloodstream using Rani’s unique route of administration. After

This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States. Upon

The submission was made under the company’s existing Investigational New Drug (IND) application. The Phase IIb study of ORMD-0801 for type 2 diabetics is designed to generate ample